Metabolism and disposition of a potent and selective GABA-A α2/3 receptor agonist in healthy male volunteers

Drug Metabolism and Disposition

Volumn 34, Issue 6, 2006, Pages 1004-1011

  Polsky Fisher, Stacey L ^a   Vickers, Stanley ^a   Cui, Donghui ^a,c   Subramanian, Raju ^a,d   Arison, Byron H ^a   Agrawal, Nancy G B ^a   Goel, Thanh V ^a   Vessey, Laura K ^a   Murphy, M Gail ^a   Lasseter, Kenneth C ^b   Simpson, Richard C ^a   Vega, Jose M ^a,d   Rodrigues, A David ^a,c  

^a MERCK RESEARCH LABORATORIES   (United States)

^b Clinical Pharmacology Associates Miami   (United States)

^c BRISTOL MYERS SQUIBB   (United States)

^d AMGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR STIMULATING AGENT; 7 (1,1 DIMETHYLETHY) 6 (2 ETHYL 2H 1,2,4 TRIAZOL 3 YLMETHOXY) 3 (2 FLUOROPHENYL) 1,2,4 TRIAZOLO[4,3 B]PYRIDAZINE; DRUG METABOLITE; PROPYLENE GLYCOL; TPA 023; UNCLASSIFIED DRUG; WATER;

ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG DISPOSITION; DRUG FECES LEVEL; DRUG HALF LIFE; DRUG METABOLISM; DRUG URINE LEVEL; FECES ANALYSIS; GLUCURONIDATION; HUMAN; HYDROXYLATION; MALE; NORMAL HUMAN; PRIORITY JOURNAL; RADIOACTIVITY; RADIOCHROMATOGRAPHY; URINALYSIS;

ADMINISTRATION, ORAL; ANTI-ANXIETY AGENTS; BIOTRANSFORMATION; CARBON RADIOISOTOPES; CHROMATOGRAPHY, LIQUID; FECES; GLUCURONIDES; HUMANS; HYDROXYLATION; MALE; MASS SPECTROMETRY; PYRIDAZINES; RECEPTORS, GABA-A; TRIAZOLES;

EID: 33646780891     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.105.008193     Document Type: Article

References (26)

1. Atack JR, Wafford KA, Tye SJ, Cook SM, Sohal B, Pike A, Sur C, Melillo D, Bristow L, Bromidge F, et al. (2006) TPA023 [7-(1,1-dimethylethyl)-6-(2-ethyl- 2H- 1,2,4-triazol-3-ylmethoxy)-3-(2-fluorophenyl)-1,2,4-triazolo[4,3-b] pyridazine], an agonist selective for α2-and α3-containing GABAA receptors, is a nonsedating anxiolytic in rodents and primates. J Pharmacol Exp Ther 316:410-422.
2. Backman JT, Olkkola KT, and Neuvonen PJ (1996) Rifampin drastically reduces plasma concentrations and effects of oral midazolam. Clin Pharmacol Ther 59:7-13.
3. Barnard EA, Skolnick P, Olsen RW, Mohler H, Sieghart W, Biggio G, Braestrup C, Bateson AN, and Langer SZ (1998) International Union of Pharmacology. XV. Subtypes of -aminobutyric acid A receptors: classification on the basis of subunit structure and receptor function. Pharmacol Rev 50:291-313.
4. Blackaby WP, Atack JR, Bromidge F, Castro JL, Goodacre SC, Hallett DJ, Lewis RT, Marshall GR, Pike A, Smith AJ, et al. (2006) Imidazo[1,2-a]pyrimidines as functionally selective GABA(A) ligands. Bioorg Med Chem Lett 16:1175-1179.
5. Carling RW, Madin A, Guiblin A, Russell MG, Moore KW, Mitchinson A, Sohal B, Pike A, Cook SM, Ragan IC, et al. (2006) 7-(1,1-Dimethylethyl)-6-(2-ethyl- 2H-1,2,4-triazol-3-ylmethoxy)-3-(2-fluorophenyl)-1,2,4-triazolo[4,3-b] pyridazine: a functionally selective gamma-aminobutyric acid (A) (GABA(A)) alpha2/alpha3-subtype selective agonist that exhibits potent anxiolytic activity but is not sedating in animal models. J Med Chem 48:7089-7092.
6. Chebib M and Johnston GAR (2000) GABA-activated ligand gated ion channels: medicinal chemistry and molecular biology. J Med Chem 43:1427-1447.
7. Goodacre SC, Hallett DJ, Carling RW, Castro JL, Reynolds DS, Pike A, Wafford KA, Newman R, Atack JR, and Street LJ (2006a) Imidazo[1,2-a]pyrazin-8- ones, imidazo[1,2-d][1,2,4]triazin-8-ones and imidazo[2,1-f][1,2,4]triazin-8- ones as alpha2/alpha3 subtype selective GABA(A) agonists for the treatment of anxiety. Bioorg Med Chem Lett 16:1582-1585.
8. Goodacre SC, Street LJ, Hallett DJ, Crawforth JM, Kelly S, Owens AP, Blackaby WP, Lewis RT, Stanley J, Smith AJ, et al. (2006b) Imidazo[1,2- a]pyrimidines as functionally selective and orally bioavailable GABA(A)alpha2/alpha3 binding site agonists for the treatment of anxiety disorders. J Med Chem 49:35-38.
9. A receptor subtypes. Eur Neuropsychopharmacol 6:119-125.
10. Greenblatt DJ, von Moltke LL, Harmatz JS, Mertzanis P, Graf JA, Durol ALB, Counihan M, Roth-Schechter B, and Shader RI (1998) Kinetic and dynamic interaction study of zolpidem with ketoconazole, itraconazole and fluconazole. Clin Pharmacol Ther 64:661-671.
11. Hwang TL and Shaka AJ (1992) Cross relaxation without TOCSY: transverse rotating-frame Overhauser effect spectroscopy. J Am Chem Soc 114:3157-3159.
12. Jennings AS, Lewis RT, Russell MG, Hallett DJ, Street LJ, Castro JL, Atack JR, Cook SM, Lincoln R, Stanley J, et al. (2006) Imidazo[1,2- b][1,2,4]triazines as alpha2/alpha3 subtype selective GABA(A) agonists for the treatment of anxiety. Bioorg Med Chem Lett 16:1477-1480.
13. A receptor pharmacology. Pharmacol Ther 69:173-198.
14. 1 subtype. Nat Neurosci 3:587-592.
15. Olkkola KT, Backman JT, and Neuvonen PJ (1994) Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole and itraconazole. Clin Pharmacol Ther 55:481-485.
16. Rudolph U, Crestani F, and Mohler H (2001) GABAA receptor subtypes; dissecting their pharmacological functions. Trends Pharmacol Sci 22:188-194.
17. Russell MG, Carling RW, Street LJ, Hallett DJ, Goodacre S, Mezzogori E, Reader M, Cook SM, Bromidge FA, Newman R, et al. (2006) Discovery of imidazo[1,2-b][1,2,4]triazines as GABA(A) alpha2/alpha3 subtype selective agonists for the treatment of anxiety. J Med Chem 49:1235-1238.
18. Schmider J, Brockmoller J, Arnold G, Bauer S, and Roots I (1999) Simultaneous assessment of CYP3A4 and CYP1A2 activity in vivo with alprazolam and caffeine. Pharmacogenetics 9:725-734.
19. Summers MF, Marzilli LG, and Bax A (1986) Complete 1H and 13C assignments of coenzyme B12 through the use of new two-dimensional NMR experiments. J Am Chem Soc 108:4258-4294.
20. Syramek JJ, Zarotsky V, and Cutler NR (2002) Generalized anxiety disorder. Drugs 62:1635-1648.
21. Varhe A, Olkkola KT, and Neuvonen PJ (1994) Oral triazolam is potentially hazardous to patients receiving systemic antimycotics ketoconazole or itraconazole. Clin Pharmacol Ther 56:601-607.
22. Villikka K, Kivisto KT, Backman JT, Olkkola KT, and Neuvonen PJ (1997) Triazolam is ineffective in patients taking rifampin. Clin Pharmacol Ther 61:8-14.
23. Wang Z, Gorski JC, Hamman MA, Huang SM, Lesko LJ, and Hall SD (2001) The effects of St John's wort (Hypericum perforatum) on human cytochrome P450 activity. Clin Pharmacol Ther 70:317-326.
24. Yasui N, Kondo T, Otani K, Furukori H, Kaneko S, Ohkubo T, Nagasaki T, and Sugawara K (1998) Effect of itraconazole on the single oral dose pharmacokinetics of alprazolam. Psychopharmacology 139:269-273.
25. Yeh KC and Remphrey K (1990) A simplex optimization program. Pharm Res (NY) 7:S244.
26. B receptors in mammalian brain: potential targets for drug development. Drug Dev Res 21:161-167.